Showing 1961-1970 of 5771 results for "".
- 2021 ASCRS Annual Meeting Moved to Las Vegas in Julyhttps://modernod.com/news/2021-ascrs-annual-meeting-moved-to-las-vegas-in-july/2478825/The American Society of Cataract and Refractive Surgery (ASCRS) announced that the 2021 ASCRS Annual Meeting, previously scheduled to take place in San Francisco in August, is now scheduled to be held July 23–27 in Las Vegas, Nevada, at the Mandalay Bay Convention Center. “Due to the
- Verana Health Announces Real-World Data and Data Science Collaboration Agreement with Janssenhttps://modernod.com/news/verana-health-announces-real-world-data-and-data-science-collaboration-agreement-with-janssen/2478805/Verana Health announced a research collaboration agreement with Janssen Research & Development (Janssen). The research collaboration will focus on curating real-world data and driving data science applications in the areas of ophthalmology and urology. Financial terms of the agreement
- Surface Ophthalmics Announces First Patient Dosed in Head-to-Head Phase 2 Trial for SURF-100 for Chronic Dry Eye Diseasehttps://modernod.com/news/surface-ophthalmics-announces-first-patient-dosed-in-head-to-head-phase-2-trial-for-surf-100-for-chronic-dry-eye-disease/2478802/Surface Ophthalmics announced that the first patient has been dosed in the phase 2 clinical trial for its investigational product SURF-100 (mycophenolate sodium and betamethasone sodium phosphate in Klarity vehicle) for the treatment of chronic dry eye disease. SURF-100 utilizes a new an
- DORC Announces Health Canada Approval of Tissueblue for Staining of the ILM During Vitreoretinal Surgeryhttps://modernod.com/news/dorc-announces-health-canada-approval-of-tissueblue-for-staining-of-the-ilm-during-vitreoretinal-surgery/2478799/DORC has announced that it has received notification from Health Canada that the application for Tissueblue (Brilliant Blue G Ophthalmic Solution 0.025%) has been approved and will be available later in 2021 via Innovamed, DORC’s local distributor partner. Tissueblue is the first dye approved by
- Leo Lens Pharma Announces Corporate Name Change to MediPrint Ophthalmicshttps://modernod.com/news/leo-lens-pharma-announces-corporate-name-change-to-mediprint-ophthalmics/2478794/Leo Lens Pharma has announced a corporate name change to MediPrint Ophthalmics, effective immediately. The company also announced it has successfully closed an over-subscribed Seed round fundraising. The company’s rebranding to MediPrint Ophthalmics is based on input from stakeholders and
- MeiraGTx Announces AAV-CNGA3 Granted Fast Track Designation by FDA for Treatment of Achromatopsiahttps://modernod.com/news/meiragtx-announces-aav-cnga3-granted-fast-track-designation-by-fda-for-treatment-of-achromatopsia/2478795/MeiraGTx Holdings announced that the FDA has granted Fast Track designation to its AAV-CNGA3 gene therapy product candidate for the treatment of achromatopsia (ACHM) caused by mutations in the CNGA3 gene. ACHM is an inherited retinal disease that severely limits a per
- Surface Ophthalmics Announces Positive Topline Results From Phase 2 Trial for SURF-201 for the Treatment of Post-Cataract Surgery Pain and Inflammationhttps://modernod.com/news/surface-ophthalmics-announces-positive-topline-results-from-phase-2-trial-for-surf-201-for-the-treatment-of-post-cataract-surgery-pain-and-inflammation/2478781/Surface Ophthalmics announced positive topline results from the phase 2 trial for SURF-201, an investigational therapy for the treatment of post-cataract surgery pain and inflammation. With twice-daily dosing, SURF-201 met its primary endpoints of absence of inflammation at both Day 8 and Day 15.
- Ocuphire Announces Publication of ORION-1 Phase 2 Results for Nyxolhttps://modernod.com/news/ocuphire-announces-publication-of-orion-1-phase-2-results-for-nyxol-in-clinical-ophthalmology/2478779/Ocuphire Pharma announced that results from its ORION-1 phase 2 clinical trial evaluating the safety and efficacy of Nyxol in glaucoma and presbyopia have been published in Clinical Ophthalmology. The paper, titled “Phentolamine Mesylate Ophthalmic Solution Provides Lasting Pupil
- CooperVision Announces 5 mm BOZD Customization for Paragon CRT and CRT Dual Axis Lenseshttps://modernod.com/news/coopervision-announces-5-mm-bozd-customization-for-paragon-crt-and-crt-dual-axis-lenses/2478769/CooperVision Specialty EyeCare announced that it has begun offering 5 mm back optic zone diameter (BOZD) customization for Paragon CRT and Paragon CRT Dual Axis contact lenses. The new option joins several existing customization choices, further expanding myopia management possibilities for eye c
- Topcon Announces eyeRISE 2021 Virtual Symposia & Expohttps://modernod.com/news/topcon-announces-eyerise-2021-virtual-symposia-expo/2478765/Topcon Healthcare announced it will host a 2-day virtual symposia and expo called eyeRISE, on February 9-10, 2021. eyeRISE, or Eye Research Innovation Symposia & Expo, is a new, multi-disciplinary virtual congress showcasing the latest innovations in eye care. It will feature three sol